dennis mccain
  • Home
  • Investing
    • Best Ideas
    • New Highs
    • Dividend Increases
    • Dividend Kings
    • Div Aristocrats
    • Div Champions
    • Business Dev Cos
    • Monthly Dividends
  • Options
    • Weekly Options
  • Photography
    • Photography Gear
    • Hiking Trails
  • Biography
  • Index
  • Contact Me

Best Ideas This Week

These companies are estimated to have a very nice one year total return on investment.

Home

Best Ideas 25 February 2018

2/23/2018

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
QuinStreet, Inc., an Internet performance marketing and media company, provides customer acquisition services for its clients in the United States and internationally. It offers online marketing services to its clients in the form of qualified leads, inquiries, clicks, calls, applications, customers, display advertisements, or impressions through its Websites or third-party publishers. The company provides its services in various verticals, such as financial services, education, business-to-business technology, and home services. QuinStreet, Inc. was founded in 1999 and is headquartered in Foster City, California.
(Summary) (Company) (Chart)
25 February 2018
Price $13.18
1yr Target $11.83
Analysts 3
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain %
Yield 0.00%
1yr Tot Return %

P/E 
PEG 
Beta 


EPS (ttm) $
EPS next yr $
Forward P/E 
EPS next 5yr %
1yr Price Support $

Market Cap $ Bil
Revenues $ Bil
Earnings $ Mil
Profit Margin %

Quick Ratio 
Current Ratio 
Debt/Equity 

1yr RevGR %
3yr RevGR %
5yr RevGR %

1yr EarnGR %
3yr EarnGR %
5yr EarnGR %

1yr DivGR %
3yr DivGR %
5yr DivGR %

ROA %
ROE %


Valhi, Inc. engages in the chemicals, component products, waste management, and real estate businesses worldwide. The company's Chemicals segment produces and markets titanium dioxide pigments (TiO2), which are white inorganic pigments used in various applications by paint, plastics, decorative laminate, and paper manufacturers. It offers TiO2 under the Kronos name through agents and distributors. This segment also offers iron-based chemicals, titanium oxychlorides, and titanyl sulfates. Its Component Products segment manufactures mechanical and electrical cabinet locks, and other locking mechanisms for use in ignition systems, mailboxes, file cabinets, desk drawers, tool storage cabinets, vending and gaming machines, medical cabinetry security, electronic circuit panels, storage compartments, and gas station security applications. This segment also provides stainless steel exhaust components, gauges, throttle controls, trim tabs, hardware, and accessories primarily for performance and ski/wakeboard boats. The company's Waste Management segment processes, treats, stores, and disposes radioactive, hazardous, toxic, and other wastes. This segment serves industrial companies, such as nuclear utilities, chemical, aerospace and electronics businesses, and governmental agencies. Its Real Estate Management and Development segment provides utility services to industrial and municipal customers; owns real properties; and develops land holdings for commercial, industrial, and residential purposes. Valhi, Inc. also offers insurance brokerage and risk management services, and holds marketable securities and other investments. The company was founded in 1932 and is based in Dallas, Texas. Valhi, Inc. is a subsidiary of Contran Corporation.
​(Summary) (Company) (Chart)
25 February 2018
Price $5.84
1yr Target $5.00
Analysts 1
Dividend $0.08
Payout Ratio %

1yr Cap Gain %
Yield %
1yr Tot Return %

P/E 
PEG 
Beta 
​
EPS (ttm) $
EPS next yr $
Forward P/E 
EPS next 5yr %
1yr Price Support $

Market Cap $ Bil
Revenues $ Bil
Earnings $ Mil
Profit Margin %

Quick Ratio 
Current Ratio 
Debt/Equity 
​

1yr RevGR %
3yr RevGR %
5yr RevGR %

1yr EarnGR %
3yr EarnGR %
5yr EarnGR %

1yr DivGR %
3yr DivGR %
5yr DivGR %

ROA %
ROE %
​

Pure Storage, Inc. engages in building a data platform that enables businesses to enhance performance and reduce complexity and costs worldwide. The company delivers its data platform through Purity Operating Environment, an optimized software for solid-state memory that offers enterprise-class storage and protocol services; FlashArray and FlashBlade optimized hardware products for solid-state memory to enhance the performance and density of flash, optimize its advanced software services, and reduce solution cost for customers; Pure1, a cloud-based management and support software; and FlashStack, a converged infrastructure solution. Its data platform is used for a range of storage use cases, including database applications, large-scale analytics, private and public cloud infrastructure, Webscale applications, virtual server infrastructure, and virtual desktop infrastructure; and helps customers scale their businesses through real-time and accurate analytics, increase employee productivity, improve operational efficiency, and deliver compelling user experiences to their customers and partners. The company serves large and mid-size organizations across various industries, such as cloud-based software and service providers, consumer Web, education, energy, financial services, government, healthcare, manufacturing, media, retail, and telecommunications through a network of distribution and channel partners. The company was formerly known as OS76, Inc. and changed its name to Pure Storage, Inc. in January 2010. Pure Storage, Inc. was founded in 2009 and is headquartered in Mountain View, California.
​(Summary) (Company) (Chart)
25 February 2018
Price $21.71
1yr Target $20.85
Analysts 20
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain %
Yield 0.00%
1yr Tot Return %

P/E 
PEG 
Beta 
​
EPS (ttm) $
EPS next yr $
Forward P/E 
EPS next 5yr %
1yr Price Support $

Market Cap $ Bil
Revenues $ Bil
Earnings $ Mil
Profit Margin %

Quick Ratio 
Current Ratio 
Debt/Equity 
​

1yr RevGR %
3yr RevGR %
5yr RevGR %

1yr EarnGR %
3yr EarnGR %
5yr EarnGR %

1yr DivGR %
3yr DivGR %
5yr DivGR %

ROA %
ROE %
​

0 Comments

Best Ideas 18 February 2018

2/18/2018

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
HealthEquity, Inc. provides various solutions for managing health care accounts, health reimbursement arrangements, and flexible spending accounts for health plans, insurance companies, and third-party administrators in the United States. Its products and services include healthcare saving and spending platform, a cloud-based platform for individuals to make health saving and spending decisions, pay healthcare bills, compare treatment options and prices, receive personalized benefit and clinical information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts. The company also offers online-only investment advisory services through HealthEquity Advisor, a Web-based tool; and healthcare incentives that enable its employer partners and health plan partners to offer, and its members to earn, financial incentives for participation in wellness programs. HealthEquity, Inc. was founded in 2002 and is headquartered in Draper, Utah.
(Summary) (
Company) (Chart)
18 February 2018
Price $54.86
1yr Target $58.36
Analysts 11
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 6.37%
Yield 0.00%
1yr Tot Return 6.37%

P/E 73.84
PEG 1.86
Beta 1.40


EPS (ttm) $0.73
EPS next yr $0.93
Forward P/E 59.12
EPS next 5yr 39.67%
1yr Price Support $

Market Cap $3.31 Bil
Revenues $215.90 Mil
Earnings $45.50 Mil
Profit Margin %

Quick Ratio 13.00
Current Ratio 13.00
Debt/Equity 0.00


1yr RevGR %
3yr RevGR %
5yr RevGR %

1yr EarnGR %
3yr EarnGR %
5yr EarnGR %

1yr DivGR %
3yr DivGR %
5yr DivGR %

ROA 14.30%
ROE 15.10%


Celgene Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases worldwide. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma (MM), myelodysplastic syndromes (MDS), and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis and psoriasis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. The company's products also include IDHIFA, a small molecule inhibitor of the isocitrate dehydrogenase 2 to treat acute myeloid leukemia (AML); VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and AML; and THALOMID to treat patients with MM and erythema nodosum leprosum. Its clinical stage products comprise OTEZLA for use in treating various immune-inflammatory diseases; luspatercept for the treatment of patients with beta-thalassemia and MDS; CC-486 to treat MDS, AML, and solid tumors; LSD1 inhibitor to treat non-hodgkin lymphoma and solid tumors; CC-122 and CC-220 to treat hematological and solid tumor cancers, and inflammation and immunology diseases; CC-92480 to treat multiple myeloma; and durvalumab, an anti-PD-L1 antibody for multiple hematological cancers. The company has a strategic collaboration with BeiGene, Ltd. to advance a PD-1 Inhibitor program for solid tumor cancers. It also has collaborative agreements with Acceleron Pharma, Inc.; Agios Pharmaceuticals, Inc.; Sutro Biopharma, Inc.; bluebird bio, Inc.; FORMA Therapeutics Holdings, LLC; OncoMed Pharmaceuticals, Inc.; NantBioScience, Inc.; AstraZeneca PLC; Lycera Corp.; Juno Therapeutics, Inc.; Nurix Inc.; and Jounce Therapeutics, Inc. The company was founded in 1980 and is headquartered in Summit, New Jersey.
​(Summary) (Company) (Chart)
18 February 2018
Price $95.26
1yr Target $124.23
Analysts 27
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 30.41%
Yield 0.00%
1yr Tot Return 30.41%

P/E 26.42
PEG 1.34
Beta 1.44
​
EPS (ttm) $3.61
EPS next yr $10.28
Forward P/E 9.27
EPS next 5yr 19.70%
1yr Price Support $

Market Cap $73.79 Bil
Revenues $13.00 Bil
Earnings $2.94 Mil
Profit Margin %

Quick Ratio 4.80
Current Ratio 5.00
Debt/Equity 1.24

​
1yr RevGR %
3yr RevGR %
5yr RevGR %

1yr EarnGR %
3yr EarnGR %
5yr EarnGR %

1yr DivGR %
3yr DivGR %
5yr DivGR %

ROA 9.70%
ROE 35.80%

​
0 Comments

Best Ideas 11 February 2018

2/11/2018

0 Comments

 
Picture
This has been a difficult week for stock buyers because it seems no matter what they bought,it went down. So it's been hard to find companies that could fit in a category called Best Ideas. But I found two. They're two companies I'll be accumulating this week because they appear to be at support levels and I believe this pullback is almost over. They should be ready to move higher. Obviously and buys have to be monitored closely in a falling market, but markets don't go up or down forever. This could be the week these two turnaround. Good Luck.
Picture
Exelixis, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of new medicines with the potential to enhance care and outcomes for people with cancer. The company's products include CABOMETYX for the treatment of patients with advanced renal cell carcinoma, who have received prior anti-angiogenic therapy; and COMETRIQ for the treatment of patients with progressive, metastatic medullary thyroid carcinoma. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors, which has shown clinical anti-tumor activity in approximately 20 forms of cancer and is the subject of a broad clinical development program. It also offers COTELLIC (cobimetinib), a selective inhibitor of MEK, in combination with vemurafenib for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma in the United States; and in combination with vemurafenib in other territories, including the European Union, Switzerland, Canada, Australia, and Brazil. Exelixis, Inc. has collaboration and license agreements with Ipsen Pharma SAS, Genentech, Inc., GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds and programs. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
(Summary) (Company) (Chart)
11 February 2018
Price $28.21
1yr Target $34.00
Analysts 7
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 20.52%
Yield 0.00%
1yr Tot Return 20.52%

P/E 57.22
PEG 1.24
Beta 1.83

EPS (ttm) $0.49
EPS next yr $0.78
Forward P/E 36.31
EPS next 5yr 46.00%
1yr Price Support $35.88

Market Cap $8.47 Bil
Revenues $410.00 Mil
Earnings $150.90 Mil
Profit Margin 36.80%

Quick Ratio 4.30
Current Ratio 4.30
Debt/Equity 0.00
​
1yr RevGR 515.04%
3yr RevGR 81.70%
5yr RevGR %-7.95

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA 26.10%
ROE 101.20%

Weibo Corporation operates as a social media platform for people to create, distribute, and discover Chinese-language content. It operates through two segments, Advertising and Marketing Services, and Other Services. The company offers self-expression products that enable its users to express themselves on its platform; social products to promote social interaction between users on its platform; discovery products to help users discover content on its platform; and notifications to notify users on Weibo account activities through SMS or push notification on their device. It also provides third-party online games, including role playing, card, strategy, and real life simulation games, as well as various services and functions to VIP members; and develops mobile apps comprising Weibo Headlines that aggregates news and information from Weibo and other online sources, as well as Weibo Weather, a weather app. In addition, the company offers advertising and marketing solutions, such as social display ads; and promoted feeds, accounts, and trends to enable its customers to promote their brands and conduct marketing activities. Further, it provides products that allow its platform partners to link their Websites and mobile apps to its platform, enabling their users to share content to Weibo; application programming interfaces, which allow third-party developers to build apps to serve individual and organization users; Weibo Credit that allows its users to purchase in-game virtual items and other fee-based services on Weibo. The company was formerly known as T.CN Corporation and changed its name to Weibo Corporation in 2012. The company was founded in 2009 and is headquartered in Beijing, China. Weibo Corporation is a subsidiary of SINA Corporation.
(Summary) (Company) (Chart)
11 February 2018
Price $115.35
1yr Target $118.16
Analysts 22
Dividend $2.43
Payout Ratio 0.00%

1yr Cap Gain 2.43%
Yield 0.00%
1yr Tot Return 0.00%

P/E 98.25
PEG 1.50
Beta 2.63
​
EPS (ttm) $1.17
EPS next yr $2.73
Forward P/E 42.27
EPS next 5yr 65.50%
1yr Price Support $178.81

Market Cap $27.02 Bil
Revenues $985.40 Mil
Earnings $264.60 Mil
Profit Margin 26.85%

Quick Ratio 2.20
Current Ratio 2.20
Debt/Equity 0.00

1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA 21.00%
ROE 30.10%

0 Comments

Best Ideas 4 February 2018

2/4/2018

0 Comments

 
Picture
Here's a couple of stock ideas I'm looking at for next week. These are companies I'll consider investing in with any funds that become available in my accounts. I believe each of these has a greater potential return than analysts currently expect. 

​As with all of my investments, I'll start with a small position and then add to that position over time through dividend reinvestment, the sale of stock options and direct purchases on the open market.
Picture
I.D. Systems, Inc. develops, markets, and sells wireless machine-to-machine solutions in the United States and internationally. The company offers integrated wireless solutions that utilize radio frequency identification, Wi-Fi, satellite or cellular communications, sensor technologies, and software to control, track, monitor, and analyze industrial vehicles, rental vehicles, and transportation assets. It provides industrial and rental fleet asset management products, including on-asset hardware with mounting and user-interface options that provide an autonomous means of asset control and monitoring; wireless asset managers that link the mobile assets being monitored with the customer's computer network or to a remotely hosted server; server software, which manages data communications between the system's database and wireless asset managers or on-asset hardware; and client software. The company also offers transportation asset management products comprising on-asset hardware configurations to address various remote asset types; VeriWise Intelligence Portal, a hosted Website that provides Internet access to client asset information; and a direct data feed through XML or Web services. In addition, it provides hosting, maintenance, and customer support and consulting services, as well as software as a service. The company markets and sells its solutions directly to commercial and government sectors in automotive manufacturing, retail, shipping, freight transportation, heavy industry, wholesale distribution, aerospace and defense, homeland security, and vehicle rental markets, as well as through original equipment manufacturers and industrial equipment dealers. I.D. Systems, Inc. was founded in 1993 and is headquartered in Woodcliff Lake, New Jersey.
(Summary) (Company) (Chart)
1 January 2017
Price $6.94
1yr Target $8.20
Analysts 3
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 18.15%
Yield 0.00%
1yr Tot Return 18.15%

P/E ---
PEG ---
Beta 0.05

EPS (ttm) $-0.38
EPS next yr $0.37
Forward P/E 18.76
EPS next 5yr 30.00%
1yr Price Support $11.10

Market Cap $119.23 Mil
Revenues $39.00 Mil
Earnings $-5.10 Mil
Profit Margin ---

Quick Ratio 1.30
Current Ratio 1.50
Debt/Equity 0.00

1yr RevGR -11.88%
3yr RevGR -2.66%
5yr RevGR -1.30%

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -10.40%
ROE -25.20%

Ampio Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development of therapies for the treatment of prevalent inflammatory conditions in the United States. The company is developing compounds that decrease inflammation by inhibiting specific pro-inflammatory compounds by affecting specific pathways at the protein expression and at the transcription level; activating specific phosphatase or depleting available phosphate needed for the inflammation process; and decreasing vascular permeability. Its product pipeline includes Ampion, an intra-articular injection for the treatment of osteoarthritis of the knee; and Optina, which has completed Phase II clinical trials for diabetic macular edema. Ampio Pharmaceuticals, Inc. is headquartered in Englewood, Colorado.
(Summary) (Company) (Chart)
4 February 2018
Price $3.05
1yr Target $14.00
Analysts 1
Dividend $0.00
Payout Ratio 0.00%

1yr Cap Gain 359.01%
Yield 0.00%
1yr Tot Return 359.01%

P/E ---
PEG ---
Beta -0.18


EPS (ttm) $-0.20
EPS next yr ---
Forward P/E ---
EPS next 5yr ---
1yr Price Support ---

Market Cap $193.98 Mil
Revenues ---
Earnings $-12.20 Mil
Profit Margin ---

Quick Ratio 1.00
Current Ratio 1.00
Debt/Equity ---


1yr RevGR ---
3yr RevGR ---
5yr RevGR ---

1yr EarnGR ---
3yr EarnGR ---
5yr EarnGR ---

1yr DivGR ---
3yr DivGR ---
5yr DivGR ---

ROA -103.40%
ROE -319.20%


0 Comments
    Picture
    Dennis McCain

    Author

    I am an Individual Investor with specific interest in long term growth and then enhancing my returns with income from dividends and derivatives. I don't recommend stocks to anyone (it's a good way to lose friends) and no one reading this should misinterpret my blog as a recommendation for any type of investment. I am writing this solely for myself and my kids.

    Picture
    Top 100 Blogs for Dividend Investors

    Archives

    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014

    DISCLAIMER
     I am not a licensed investment adviser, and I am not providing investment advise for you on this site. Please consult with an investment professional before you invest your money. Any opinion expressed here should not be treated as investment advice. I am not liable for any losses suffered by any party because of data or information published on this blog. Past performance is not a guarantee of future performance. Unless your investments are FDIC insured, they may decline in value.

    Categories

    All

    RSS Feed

Powered by Create your own unique website with customizable templates.